chufangao/CTO huggingface dataset:
Clinical trial NCT03930615: Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 220.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-21
Primary completion date: 2021-10-27
Completion date: 2022-03-16
Baseline population: Treated participants
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04091360: A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
Official title: A Phase II, Randomised Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Pressurised Metered Dose Inhaler in Patients With COPD
Sponsor: Verona Pharma plc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-04-29
Primary completion date: 2020-12-10
Completion date: 2021-01-21
Plan to share individual participant data: NO
Clinical trial NCT05393635: ITIL-168 in Advanced Solid Tumors
Official title: A Phase 1, Open-Label, Multicenter Study Evaluating the Safety, Feasibility, and Preliminary Efficacy of ITIL-168 With Pembrolizumab in Subjects With Advanced Solid Tumors
Acronym: DELTA-2
Sponsor: Instil Bio (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: business decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-08-31
Primary completion date: 2022-12-08
Completion date: 2022-12-08
Plan to share individual participant data: NO
Clinical trial NCT03324828: Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown)
Official title: Double-blind Randomized Clinical Trial to Compare Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown)
Acronym: SONRISA
Sponsor: Hospital San Carlos, Madrid (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COVID-19
Enrollment: 170.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-11-01
Primary completion date: 2020-05-29
Completion date: 2020-05-29
Clinical trial NCT02795520: Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
Official title: Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
Sponsor: OncoTherapy Science, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: slow patient accrual
Enrollment: 32.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-04-30
Primary completion date: 2021-05-31
Completion date: 2021-09-30
Clinical trial NCT03951753: A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
Official title: The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 117.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-06-28
Primary completion date: 2021-04-08
Completion date: 2021-04-08
Baseline population: All randomized participants who received at least one dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT04015518: A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
Official title: Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIb Dose-finding Study to Evaluate Safety and Efficacy of Different Subcutaneous Doses of BI 655130 in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP)
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 152.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-07-31
Primary completion date: 2020-08-06
Completion date: 2021-07-28
Baseline population: Safety analysis set (SAF): This patient set includes all patients who were randomised and received at least one dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement. Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.~The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT03021395: Efficacy of Decitabine in Clearance of MRD
Official title: Efficacy of Decitabine in Clearance of MRD
Sponsor: Institute of Hematology & Blood Diseases Hospital, China (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: The previous data needs to be analyzed.
Enrollment: 300.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2017-02-08
Primary completion date: 2021-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT03064126: RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
Official title: RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Acronym: RANGER II SFA
Sponsor: Boston Scientific Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 440.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-02
Primary completion date: 2019-11-18
Completion date: 2023-10-25
Plan to share individual participant data: NO
Clinical trial NCT04569357: Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Official title: Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Sponsor: Materia Medica Holding (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 363.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-20
Primary completion date: 2022-02-18
Completion date: 2022-02-18
Clinical trial NCT04120116: FX-322 in Adults With Stable Sensorineural Hearing Loss
Official title: A Phase 2a, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single and Repeat-Dose, Multicenter, Exploratory Efficacy Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss
Sponsor: Frequency Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 95.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-04
Primary completion date: 2020-10-06
Completion date: 2020-12-17
Baseline population: Full Analysis Set is defined as all randomized subjects who received at least one dose of study drug or placebo in the study ear per the randomized treatment schedule
Clinical trial NCT06046482: Phase II Trial of Magrolimab and Cetuximab with Pembrolizumab or Docetaxel for Recurrent/metastatic Head Neck Squamous Cell Carcinoma
Official title: Phase II Trial of Magrolimab and Cetuximab with Pembrolizumab or Docetaxel for Recurrent/metastatic Head Neck Squamous Cell Carcinoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow Accrual
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-11-28
Primary completion date: 2024-08-26
Completion date: 2024-08-26
Plan to share individual participant data: NO
Clinical trial NCT04150107: A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes
Official title: A Phase 2 Randomized, Open Label Crossover Study to Compare ORMD-0801 Given Once Daily at Bedtime to ORMD-0801 Given Three Times Daily (45-90 Minutes Before Meals) in Subjects With Type 1 Diabetes
Sponsor: Oramed, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-17
Primary completion date: 2020-02-06
Completion date: 2020-03-12
Baseline population: All patients are first administered a placebo, or is the standard of care.
Plan to share individual participant data: NO
Clinical trial NCT03588936: Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Official title: Phase 1 Study of Nivolumab in Combination With Tocilizumab for Treatment of Patients With Relapsed Hematological Malignancies Post-allogeneic Transplant
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Poor accrual and loss of funding.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-14
Primary completion date: 2020-07-15
Completion date: 2020-07-15
Plan to share individual participant data: NO
Clinical trial NCT05143489: The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast:
Official title: The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast: A Double-blinded, Randomized-control Trial
Sponsor: Maimonides Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: 1. CTs occur late at night and weekends when their is no availability of the research staff.~. No activity since a year+
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-03
Primary completion date: 2024-04-17
Completion date: 2024-04-17
Clinical trial NCT03975101: Very Small Embryonic-like Stem Cells for Knee Osteoarthritis
Official title: Autologous Very Small Embryonic-like Stem Cells(VSELs) for Knee Osteoarthritis
Sponsor: Fuda Cancer Hospital, Guangzhou (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Policy changes have contributed to the failure to carry out smoothly
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-07-05
Primary completion date: 2020-05-25
Completion date: 2020-06-15
Plan to share individual participant data: NO
Clinical trial NCT06067191: Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)
Official title: A RANDOMISED, PHASE 1B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RV299 AGAINST RESPIRATORY SYNCYTIAL VIRUS IN THE VIRAL CHALLENGE MODEL
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 82.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-08
Primary completion date: 2022-12-02
Completion date: 2022-12-02
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04032704: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Official title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Sponsor: Seagen Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study closed due to portfolio prioritization
Enrollment: 205.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-10-09
Primary completion date: 2023-11-28
Completion date: 2023-11-28
Clinical trial NCT03574857: Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance
Official title: Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance
Sponsor: University of Virginia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-01
Primary completion date: 2021-01-01
Completion date: 2021-01-01
Clinical trial NCT04667377: A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
Official title: A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 387.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-03-08
Primary completion date: 2022-09-15
Completion date: 2022-10-07
Baseline population: Full analysis set (FAS): All randomised participants who received at least one dose of trial medication and who had analysable data for at least one efficacy endpoint, using planned maintenance treatment.
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement.~Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.~The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT03422679: Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Official title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway
Sponsor: Cellestia Biotech AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: business reason
Enrollment: 79.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-05
Primary completion date: 2022-11-11
Completion date: 2022-11-11
Plan to share individual participant data: NO
Clinical trial NCT03871829: Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Official title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab Retreatment
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee recommendation was early stop of the study for futility.
Enrollment: 88.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-31
Primary completion date: 2022-10-24
Completion date: 2023-01-10
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT02686658: Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Official title: A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 286.0 (ACTUAL)
Number of arms: 6.0
Start date: 2016-01-20
Primary completion date: 2019-09-26
Completion date: 2020-04-23
Clinical trial NCT03515629: REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
Official title: A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 5.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-02
Primary completion date: 2021-07-29
Completion date: 2021-07-29
Baseline population: Safety analysis set (SAF), defined as all enrolled participants who received any amount of study treatment.
Clinical trial NCT03721211: Imaging With [11C]Martinostat in Breast Cancer
Official title: Imaging With [11C]Martinostat in Breast Cancer
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Principal investigator left the study institution.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-01
Primary completion date: 2020-02-28
Completion date: 2024-10-31
Plan to share individual participant data: NO
Clinical trial NCT04985825: Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Official title: Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)
Acronym: I-PACE
Sponsor: Centessa Pharmaceuticals plc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Business decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-16
Primary completion date: 2022-08-17
Completion date: 2022-08-17
Plan to share individual participant data: NO
Clinical trial NCT05007041: Simultaneous RZV and aIIV4 Vaccination
Official title: Safety of Simultaneous Vaccination With Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Inactivated Influenza Vaccine (aIIV4)
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 267.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-21
Primary completion date: 2023-03-04
Completion date: 2023-06-08
Plan to share individual participant data: NO
Clinical trial NCT03901573: High-Risk Skin Cancers With Atezolizumab Plus NT-I7
Official title: A Phase 1b/2a, Open Label Study to Evaluate Anti-tumor Efficacy and Safety of rhIL-7-hyFc (NT-I7) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Anti-PD-1/PD-L1 naïve or Relapsed/Refractory High-risk Skin Cancers
Sponsor: NeoImmuneTech (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Strategic decision by sponsor
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-26
Primary completion date: 2023-08-15
Completion date: 2023-08-15
Plan to share individual participant data: NO
Clinical trial NCT02978885: Imaging of Peri-operative (periOP) Lung Injury
Official title: In Vivo Imaging of Peri-operative (periOP) Destructive Processes in the Lung
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Poor enrollment
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-11
Primary completion date: 2020-02-05
Completion date: 2020-02-05
Baseline population: Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1). Study terminated due to poor enrollment.
Limitations and caveats: Study terminated due to poor enrollment. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02424851: Optimising Renal Outcome in Myeloma Renal Failure
Official title: A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min
Acronym: OPTIMAL
Sponsor: Oxford University Hospitals NHS Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-11-30
Primary completion date: 2020-04-20
Completion date: 2020-04-20
Clinical trial NCT02631070: A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Official title: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions.
Acronym: MEDALIST
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 229.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-09
Primary completion date: 2019-06-18
Completion date: 2020-11-26